Following FDA investigation clearing the recent death as unrelated, the agency lifted the voluntary hold on Sarepta Therapeutics’ Elevidys gene therapy shipments for ambulatory patients with Duchenne muscular dystrophy (DMD). The treatment, previously paused due to safety concerns including acute liver toxicity in some patients, resumed distribution with restrictions. The FDA continues monitoring safety, maintaining the hold on non-ambulatory patients until further data support broader access.